Also, I'd add that ADAMS is a carer-derived assessment.
I can only imagine that there is a degree of enthusiasm and hope from the Carers (possibly with an overflow impact on the patient??) in the performance of these trials, particularly with positive Ph1 results publicly available.
To see no benefit, if you were on the Placebo arm, would be kind of demoralising and even more so if you know someone on the NTI 164 arm that was benefitting.
NTI Price at posting:
7.9¢ Sentiment: None Disclosure: Held
